Hi Gary
the valuation is extremely difficult to determine. If we pull all the "happy go lucky" and all the "it's a scam" out of the equation, there are a number of uncertain factors that make it extremely difficult to make a valuation. in addition to the completely obvious uncertainty factors such as approval, possible SOC, price agreements with regulators, etc., we are also faced with the question of what we earn per treatment. People need to understand that this may be one of the most expensive production costs per item for an approved product (we assume we get an approval). Therefore, it is wrong to compare with previously approved products which to a much greater extent can be "mass produced".
To this problem must be added that perhaps the largest part of the "sales price" is expenses for the production of DCVax which is done by an external supplier .. this means we actually share the "profit" with this supplier and make it practically impossible to value the company itself after an approval, until we get all the information.
If there's one thing Wall Street and market dont like, it’s uncertainty and we have lots of it and one thing market likes is concrete numbers and we have none of them ..
before we get clarification on these issues we will not get a significant increase in MC even a journal and an approval can’t change it .. we have to see numbers and profit before things will change.
News 
Market Data 
Discover 
